<DOC>
	<DOCNO>NCT00659555</DOCNO>
	<brief_summary>This two-period study evaluate effect repeat oral dose ketoconazole pharmacokinetics single dose pazopanib administer eye drop</brief_summary>
	<brief_title>Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib ( GW786034 ) Eye Drops</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Inclusion criterion : Healthy determine trained health care professional , base medical evaluation include medical history , physical examination , laboratory test 12lead ECG . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Subjects ALT AST value normal limit exclude enrollment . Male female great 18 year age . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation/occlusion hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample show simultaneous follicle stimulate hormone ( FSH ) &gt; 40MIU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) may use confirm woman postmenopausal ] . BMI within range 1830 kg/m2 ( inclusive ) . Capable give write informed consent comply requirement restriction list consent form . QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . Current alcohol illicit drug use , judgment Investigator , would interfere subject 's ability comply dose schedule protocolspecified evaluation . For example , history regular alcohol consumption ( define ) within 6 month screen would exclude subject . Regular alcohol consumption : average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 ml ) 80 proof distil spirit . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . HIV require treatment study period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription , nonprescription , illicit drug , include vitamin , herbal dietary supplement ( include St. John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . ( Note : restriction include ocular prescription nonprescription drug . ) History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Any contraindication use ketoconazole detailed package insert . Where participation study would result donation blood blood product excess 500 ml within 56 day period . Pregnant female determine positive urine hCG test screen prior dosing . Women plan breastfeed infant study period . Presence ongoing ocular disease time screen . Any eye surgery within three month prior first dose study medication . An unwillingness refrain wear contact lens study completion followup visit . Urinary continine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , Seville oranges ( found orange marmalade ) , grapefruit grapefruit juice 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>vascular endothelial growth factor ,</keyword>
	<keyword>drug interaction ,</keyword>
	<keyword>angiogenesis ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>age-related macular degeneration ,</keyword>
	<keyword>pazopanib ,</keyword>
	<keyword>ketoconazole</keyword>
</DOC>